Tech Company Financing Transactions
Puma Biotechnology Funding Round
Adage Capital Management, Hambrecht & Quist Capital Management and OrbiMed invested in a $55 million funding round for Puma Biotechnology. The financing round was announced on 10/5/2011.
Transaction Overview
Company Name
Announced On
10/5/2011
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the private placement will be used primarily to fund the continued clinical development of neratinib.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10880 Wilshire Blvd. 2150
Los Angeles, CA 90024
USA
Los Angeles, CA 90024
USA
Phone
Website
Email Address
Overview
Puma Biotechnology, Inc. is a development-stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alan Auerbach
Chief Financial Officer
Maximo Nougues
Chief Medical Officer
Richard Bryce
VP - Bus. Development
Jeffrey Ludwig
VP - Regulatory Affairs
Douglas Hunt
Browse more venture capital transactions:
Prev: 10/5/2011: GluMetrics venture capital transaction
Next: 10/5/2011: 1Life Healthcare venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs